Skip to main content
SpringerLink
Log in

Drug Treatment Options for Irritable Bowel Syndrome

Managing for Success

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Irritable bowel syndrome (IBS) is a functional gut disorder the diagnosis of which is based on clinical symptoms as set forth by the Rome criteria. As the population ages, especially with the population of patients >75 years of age expanding greatly over the next 10 years, IBS is becoming one of the most common diseases of the elderly. Thus far, developing treatment strategies for patients with IBS has been difficult because of the lack of pharmacological targets and the wide range of symptomatology. Additionally, demonstration of a therapeutic benefit is difficult in the presence of a high placebo response observed regardless of the therapy employed. Fibre, antidiarrhoeals and antispasmodics all play some role in the symptomatic treatment of IBS. With the evolution of IBS as a disorder of visceral hypersensitivity, new drugs have been developed that target the enteric nervous system. Tricyclic antidepressants (TCAs) have been found to target the enteric neurons and play a role in pain modulation. Currently, the TCAs are recommended only for severe cases of IBS pain. The newest class of drugs to be approved for use in IBS are the serotonin (5-hydroxytryptamine; 5-HT) antagonists. Specifically, the 5-HT3 receptor antagonists have been shown to decrease symptoms in female patients with IBS. A related class of drugs, the 5-HT4 receptor agonists, is being developed for the treatment of constipation-predominant IBS. Further investigation into the role of spinal afferent neurons in visceral hypersensitivity is at the forefront of IBS research. Several experimental drug therapies for IBS are also discussed in this review including N-methyl-D-aspartate receptor antagonists, neurokinin-1 receptor antagonists, octreotide, clonidine and the selective M3 receptor antagonist, zamifenacin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999 Sep; 45Suppl II: II43–7

    Article  PubMed  Google Scholar 

  2. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 2120–37

    Article  PubMed  CAS  Google Scholar 

  3. American Gastroenterological Association. Medical position statement: irritable bowel syndrome. Gastroenterology 1997 Jun; 112: 2118–9

    Article  Google Scholar 

  4. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci 1993 Sep; 38(9): 1569–80

    Article  PubMed  CAS  Google Scholar 

  5. Whitehead WE, Areskin LJ, Heller BR, et al. Evidence for exacerbation of irritable bowel syndrome during menses. Gastroenterology 1990; 98: 1485–9

    PubMed  CAS  Google Scholar 

  6. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987; 92: 1885–93

    PubMed  CAS  Google Scholar 

  7. Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990; 98: 1187–92

    PubMed  CAS  Google Scholar 

  8. Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40–52

    Article  PubMed  CAS  Google Scholar 

  9. Manning AP, Thompson WG, Heaton KW, et al. Towards a positive diagnosis of the irritable bowel. BMJ 1978; 2: 653–4

    Article  PubMed  CAS  Google Scholar 

  10. Drossman DA. An integrated approach to the irritable bowel syndrome. Aliment Pharmacol Ther 1999; 13Suppl. 2: 3–14

    Article  PubMed  Google Scholar 

  11. Camilleri M, Prather C. The irritable bowel syndrome: mechanisms and a practical approach to management. Ann Intern Med 1992 Jun; 116 (12 Pt 1): 1001–8

    PubMed  CAS  Google Scholar 

  12. Camilleri M, Lee JS, Viramontes B, et al. Insights into the pathophysiology and mechanisms of constipation, irritable bowel syndrome, and diverticulosis in older people. J Am Geriatr Soc 2000; 48: 1142–50

    PubMed  CAS  Google Scholar 

  13. Drossman DA. Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann Intern Med 1995 Nov; 123(9): 688–97

    PubMed  CAS  Google Scholar 

  14. De Ponti R, Malagelada JR. Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management. Pharm Ther 1998; 80(1): 49–88

    Article  Google Scholar 

  15. Talley NJ, Zinsmeister AR, Van Dyke C, et al. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101(4): 927–34

    PubMed  CAS  Google Scholar 

  16. Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 3–15

    Article  PubMed  CAS  Google Scholar 

  17. Burkitt DP, Walker ARP, Painter NS. Effect of dietary fibre on stools and transit-times, and its role in the causation of disease. Lancet 1972; 2: 1408–12

    Article  PubMed  CAS  Google Scholar 

  18. Friedman G. Diet and the irritable bowel syndrome. Gastroenterol Clin North Am 1991 Jun; 20(2): 313–24

    PubMed  CAS  Google Scholar 

  19. Francis CY, Whorwell PJ. Bran and the irritable bowel syndrome: time for reappraisal. Lancet 1994 Jul; 344: 39–40

    Article  PubMed  CAS  Google Scholar 

  20. Lambert JP, Brunt PW, Mowat NAG, et al. The value of prescribed high-fibre diets for the treatment of the irritable bowel syndrome. Eur J Clin Nutr 1991; 45: 601–9

    PubMed  CAS  Google Scholar 

  21. Cook IJ, Irvine EJ, Campbell D, et al. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome: a controlled, crossover study. Gastroenterology 1990 Jan; 98: 66–72

    PubMed  CAS  Google Scholar 

  22. Anonymous. Dietary fiber, food intolerance, and irritable bowel syndrome. Nutr Rev 1990 Sep; 48(9): 343–6

    Google Scholar 

  23. Camilleri M. Review article: clinical evidence to support current therapies of irritable bowel syndrome. Aliment Pharmacol Ther 1999 May; 13Suppl. 2: 48–53

    PubMed  Google Scholar 

  24. Cann PA, Read NW, Holdsworth CD, et al. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984 Mar; 29(3): 239–47

    Article  PubMed  CAS  Google Scholar 

  25. Lavo B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome: a double-blind placebo-controlled study. Scand J Gastroenterol 1987; 130: 77–80

    Article  CAS  Google Scholar 

  26. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol 1987; 130: 81–4

    Article  CAS  Google Scholar 

  27. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 463–8

    Article  PubMed  CAS  Google Scholar 

  28. Niaz SK, Sandrasegaran K, Renny FH et al. Post-infective diarrhea and bile acid malabsorption. J R Coll Physicians Lond. 1997 Jan–Feb; 31(1): 53–6

    PubMed  CAS  Google Scholar 

  29. Matts SG. An assessment of dicyclomine hydrochloride (Merbentyl) in the irritable colon syndrome. Br J Clin Pract 1967 Nov; 21(11): 549–51

    PubMed  CAS  Google Scholar 

  30. General Practice Research Group. Clinical trials: irritable colon syndrome treated with an antispasmodic drug. Practitioner 1976 Aug; 217: 276–80

    Google Scholar 

  31. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981 Jun; 3: 153–6

    Article  PubMed  CAS  Google Scholar 

  32. Poynard R, Naveau S, Mory B, et al. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 499–510

    Article  PubMed  CAS  Google Scholar 

  33. American College of Gastroenterology Committee on FDA Related Matters. The GI drug column. Am J Gastroenterol 1983; 78(3): 189–90

    Google Scholar 

  34. Pace F, Coremans G, Dapoigny M, et al. Therapy of irritable bowel syndrome-an overview. Digestion 1995; 56: 433–42

    Article  PubMed  CAS  Google Scholar 

  35. Van Outryve M, Milo R, Touissaint J, et al. Prokinetic treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991; 13: 49–57

    Article  PubMed  Google Scholar 

  36. Passaretti S, Tittobello A, Capozzi C, et al. Cisapride accelerated total intestinal transit in patients with irritable bowel syndrome-associated constipation. Prog Med 1987; 43Suppl. 1: 212–19

    Google Scholar 

  37. Farup PG, Hovendak N, Wetterhus S, et al. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol 1998; 33: 128–31

    Article  PubMed  CAS  Google Scholar 

  38. Anonymous. Cisapride to be withdrawn in the US. Reactions 2000 1 Apr; 395: 2

    Google Scholar 

  39. Junien JL, Riviere P. Review article: the hypersensitive gut: peripheral kappa agonists as a new pharmacological approach. Aliment Pharmacol Ther 1995; 9: 117–26

    Article  PubMed  CAS  Google Scholar 

  40. Delvaux M, Louvel D, Emmanuel L, et al. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999 Jan; 116: 38–45

    Article  PubMed  CAS  Google Scholar 

  41. Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome: a multicenter dose-response study. Dig Dis Sci 1995 Oct; 40(10): 2244–8

    Article  PubMed  CAS  Google Scholar 

  42. Su X, Gebhart GF. Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent fibers innervating the rat colon. Pain 1998; 76: 105–14

    Article  PubMed  CAS  Google Scholar 

  43. Clouse RE, Lustman PJ, Geisman RA, et al. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994; 8: 409–16

    Article  PubMed  CAS  Google Scholar 

  44. Clouse RE. Antidepressants for functional gastrointestinal syndromes. Dig Dis Sci 1994 Nov; 39(11): 2352–63

    Article  PubMed  CAS  Google Scholar 

  45. Humphrey PPA, Bountra C, Clayton N, et al. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1999; 13Suppl. 2: 31–8

    PubMed  Google Scholar 

  46. Prior A, Read NW. Reduction of rectal sensitivity and postprandial motility by granisetron, a 5-HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 175–80

    Article  PubMed  CAS  Google Scholar 

  47. Gunput MD. Review article: clinical pharmacology of alosetron. Aliment Pharmacol Ther 1999; 13Suppl. 2: 70–6

    Article  PubMed  Google Scholar 

  48. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149–59

    Article  PubMed  CAS  Google Scholar 

  49. Scott L, Perry CM. Tegaserod. Drugs 1999 Sep; 58(3): 491–6

    Article  PubMed  CAS  Google Scholar 

  50. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000 Mar; 118: 463–8

    Article  PubMed  CAS  Google Scholar 

  51. Prins NH, Van Haselen JF, Lefebvre RA, et al. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol 1999 Jul; 127(6): 1431–7

    Article  PubMed  CAS  Google Scholar 

  52. Bouras EP, Camilleri M, Burton DD, et al. Selective stimulation of colonic transit by the benzofuran 5-HT4 agonist, prucalopride, in healthy humans. Gut 1999; 44: 682–6

    Article  PubMed  CAS  Google Scholar 

  53. Kolhekar R, Gebhart GF. NMDA and quisqualate modulation of visceral nociception in the rat. Brain Res 1994 Jul; 651(1–2): 215–26

    Article  PubMed  CAS  Google Scholar 

  54. Coutinho SV, Meller ST, Gebhart GF. Intracolonic zymosan produces visceral hyperalgesia in the rat that is mediated by spinal NMDA and non-NMDA receptors. Brain Res 1996 Oct; 736(1–2): 7–15

    Article  PubMed  CAS  Google Scholar 

  55. Oh-Young L, Munakata J. Naliboff BD, et al. A double blind parallel group pilot study of the effects of CJ-11,974 and placebo on perceptual and emotional responses to rectosigmoid distention in IBS patients [abstract no. 4439]. Digestive Diseases Week: 2000 May 21–24; San Diego (CA)

  56. Hasler WL, Soudah HC, Owyang C. Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. J Pharmacol Exp Ther 1994 Mar; 268(3): 1206–11

    PubMed  CAS  Google Scholar 

  57. Viramontes B, Malcolm A, Szarka LA, et al. Dose-related effects of alpha two adrenergic agent, clonidine, on human gastrointestinal motor, transit and sensory functions [abstract no. 3656]. Digestive Diseases Week: 2000 May 21–24; San Diego (CA)

  58. Benssousan A, Talley NJ, Hing M, et al. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998 Nov; 280(18): 1585–9

    Article  Google Scholar 

  59. Lu W Chinese herbal medicine for irritable bowel syndrome [letter]. JAMA 1999 Sep; 282(11): 1035

    Article  PubMed  CAS  Google Scholar 

  60. Wallis RM. Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists. Life Sci 1995; 56(11–12): 861–8

    Article  PubMed  CAS  Google Scholar 

  61. Houghton LA, Rogers J, Whorwell PJ, et al. Zamifenacin (UK-76,654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1997 Jun; 11(3): 561–68

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, Gainesville, Florida, USA

    Rebecca C. Dunphy &  G. Nicholas Verne

Authors
  1. Rebecca C. Dunphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Nicholas Verne
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dunphy, R.C., Verne, G.N. Drug Treatment Options for Irritable Bowel Syndrome. Drugs & Aging 18, 201–211 (2001). https://doi.org/10.2165/00002512-200118030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200118030-00005

Keywords

Search

Navigation